Hyattsville, Maryland Clinical Trials

A listing of Hyattsville, Maryland clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 134 clinical trials
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for …

platelet count
alkylating agents
biological factors
Children's National Medical Center
 (5.4 away) Contact site
  • 17 Jan, 2021
  • +19 other locations
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

Background The protein mesothelin is found on many kinds of tumors. The drug LMB-100 targets cancer cells that make this protein. Researchers want to see if LMB-100 combined with another drug can help people with these tumors. Objective To find a safe dose of LMB-100 plus tofacitinib in people with …

National Institutes of Health Clinical Center
 (9.7 away) Contact site
  • 27 Dec, 2020
  • 1 location
S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)

This study proposes to test S 48168 (ARM210) in a Phase 1 trial in RYR1-RM patients, specifically. The objectives of this study are to explore the safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD)/target engagement (TE) of S 48168 (ARM210), as well as effects on muscle/motor function, and fatigue in RYR1-RM …

National Institutes of Health Clinical Center
 (9.7 away) Contact site
  • 17 Jan, 2021
  • 1 location
Safety and Tolerability of Oral Proglumide for NASH

This study is an open labelled Phase I/II clinical trial, designed to evaluate the safety and efficacy of an oral cholecystokinin (CCK) receptor antagonist, proglumide, at escalating doses in subjects with NASH. An extended use protocol has been approved for subjects completing this study that show benefit or are at …

fatty liver
liver disease
Washington DC Veterans Affairs Medical Center
 (5.8 away) Contact site
  • 23 Nov, 2020
  • +1 other locations
First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and early efficacy signs of M3258 as a single agent and co-administered with dexamethasone in participants with Relapsed Refractory Multiple Myeloma (RRMM).

progressive disease
proteasome inhibitor
refractory multiple myeloma
Georgetown University Medical Center- Research Parent
 (7.9 away) Contact site
  • 11 Nov, 2020
  • +5 other locations
Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine

This study will investigate if an intra-nasal nose spray of the drug oxytocin can decrease the amount of pressure needed from the automatic Continuous Positive Airway Pressure (CPAP) device while sleeping decreasing some of the harmful effects of low oxygen in people with sleep apnea. This study will last 35 …

obstructive sleep apnea
continuous positive airway pressure
Medical Faculty Associates
 (7.1 away) Contact site
  • 04 Aug, 2019
  • 1 location
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma

This is a Phase I, open-label multi-site trial designed to evaluate the safety of administering rapidly-generated Tumor associated antigen specific T cells (TAA-T) with the Programmed Death1 (PD-1) inhibitor Nivolumab, in relapsed/refractory lymphoma (rel/ref) patients with measurable disease (group A) or as adjunctive therapy following autologous hematopoeitic stem cell transplant(HSCT) …

colony stimulating factor
b-cell lymphoma
diffuse large b-cell lymphoma
pd-1 inhibitor
Children's National Medical Center
 (5.4 away) Contact site
  • 19 Aug, 2020
  • +1 other locations
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies

Background One type of cancer therapy takes blood cells from a person, changes them in a lab, then gives the cells back to the person. In this study, researchers are using an anti-CD22 gene, a virus, and an immune receptor to change the cells. Objective To see if giving anti-CD22 …

immunosuppressive agents
chemotherapy drugs
chemotherapy drug
National Institutes of Health Clinical Center, 9000 Rockville Pike
 (9.7 away) Contact site
  • 24 Dec, 2020
  • 1 location
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

Background Kaposi sarcoma (KS) is a cancer most often seen in people with HIV. It causes lesions. These are usually on the skin but sometimes in the lymph nodes, lungs, and gastrointestinal tract. Researchers think a combination of drugs may help treat KS. Objective To test a combination of the …

progressive disease
antiretroviral agents
cytotoxic chemotherapy
National Institutes of Health Clinical Center, 9000 Rockville Pike
 (9.7 away) Contact site
  • 01 Oct, 2020
  • 1 location
Microbial Immune and Metabolic Perturbations by Antibiotics (MIME Study)

More than 250 million courses of antibiotics are prescribed annually in the ambulatory care setting in the United States alone, including more than 40 million in children under 18 years of age. The perception that antibiotic use has minimal attendant adverse side effects contributes to the over-utilization of antibiotics in …

National Institutes of Health Clinical Center, 9000 Rockville Pike
 (9.7 away) Contact site
  • 17 Jan, 2021
  • 1 location